Drug-labels.com

AG-Montelukast (Angita Pharma, 4 mg, 5 mg): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Current status: Cancelled Pre Market
Strength:
4 mg, 5 mg

Patient Medication Information: uses, side effects, how to take - AG-Montelukast (Angita Pharma, 4 mg, 5 mg)

ABOUT THIS MEDICATION

What the medication is used for:

Asthma (for adults, adolescents and children 2 to 14 years old):

Your physician has prescribed AG-MONTELUKAST to treat your asthma or your child’s asthma, including preventing your asthma symptoms during the day and night. When taken as prescribed, AG-MONTELUKAST also prevents the narrowing of airways triggered by exercise.

AG-MONTELUKAST can be used alone or together with other medications to help with the treatment and prevention of you or your child’s asthma. Your physician will decide which combination of medicines will work best for you or your child.

Seasonal Allergic Rhinitis (for adults and adolescents 15 years and older):

Your physician has prescribed AG-MONTELUKAST to treat your seasonal allergies, including daytime and nighttime symptoms, including nasal congestion, runny nose, nasal itching, and sneezing; nasal congestion upon awakening; tearing, itchy, red, and puffy eyes.

What it does:

AG-MONTELUKAST is a leukotriene receptor antagonist that blocks substances in your lungs called leukotrienes. Leukotrienes cause narrowing and swelling of airways in your lungs. Blocking leukotrienes improves asthma symptoms and helps prevent asthma attacks. Leukotrienes also can contribute to the development of allergy symptoms. Blocking leukotrienes improves seasonal allergy symptoms (also known as hay fever or seasonal allergic rhinitis).

When it should not be used:

Do not take AG-MONTELUKAST if you or your child are allergic to any of its ingredients. See what the non-medicinal ingredients are.

What the medicinal ingredient is:

Montelukast sodium

What the non-medicinal ingredients are:

4 mg and 5 mg chewable tablet: aspartame, flavour cherry, hydroxypropylcellulose, magnesium stearate, mannitol, microcrystalline cellulose, croscarmellose sodium and red iron oxide.

Phenylketonurics: AG-MONTELUKAST 4 mg and 5 mg chewable tablets contain 0.54 and 0.67 mg phenylalanine, respectively.

10 mg film-coated tablet: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, titanium dioxide, iron oxide yellow, carnauba wax and iron oxide red.

What dosage forms it comes in:

AG-MONTELUKAST film-coated tablet: 10 mg

AG-MONTELUKAST chewable tablet : 4 mg and 5 mg.

WARNINGS AND PRECAUTIONS AG-MONTELUKAST is not for the treatment of acute asthma attacks. If an attack occurs, you or your child should follow the instructions your physician has given you for that situation.

Behavior and mood-related changes have been reported in patients taking AG-MONTELUKAST. If you or your child experience these changes while taking AG-MONTELUKAST (see “SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM”), tell your physician.

BEFORE using AG-MONTELUKAST, tell your physician if you or your child:

  • have phenylketonuria;
  • suffer from liver problems;
  • are using any other medicines;
  • have or have had any medical problems or allergies.

IMPORTANT: PLEASE READ

You should immediately inform your doctor if you or your child start to have any:

  • agitation, including aggressive behaviour or hostility (such as temper tantrums in children),
  • suicidal thoughts and actions,
  • anxiousness, depression (sad mood),
  • disorientation (inability to know correct time, place or person), dream abnormalities, hallucinations (seeing or hearing things that are not there),
  • insomnia, irritability, restlessness, sleep walking,
  • tremors.
  • Disturbance in attention, memory impairment

Use in pregnancy

Women who are pregnant or intend to become pregnant should consult their physician before taking AG-MONTELUKAST.

Use in breast-feeding

It is not known if AG-MONTELUKAST appears in breast milk. You should consult your physician before taking AG-MONTELUKAST if you are breast-feeding or intend to breast-feed.

AG-MONTELUKAST is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported very rarely with AG-MONTELUKAST may affect some patients' ability to drive or operate machinery.

If your or your child’s asthma symptoms get worse, you should contact your physician immediately.

If your asthma is made worse by exercise, you should continue to use the medicines your physician has prescribed for you to use before exercise, unless your physician tells you otherwise. You should always have your inhaled rescue medicine for asthma attacks with you in case you need it.

If your asthma is made worse by acetylsalicylic acid (ASA) (e.g., Aspirin), you should continue to avoid ASA or other non-steroidal anti-inflammatory drugs.

INTERACTIONS WITH THIS MEDICATION

In general, AG-MONTELUKAST does not interfere with other medicines that you may be taking. However, some medicines may affect how AG-MONTELUKAST works, or AG-MONTELUKAST may affect how your other medicines work. It is important to tell your physician about all drugs that you are using or plan to use, including those obtained without a prescription.

PROPER USE OF THIS MEDICATION

Usual dose:

Asthma (for adults, adolescents and children 2 to 14 years old):

Take AG-MONTELUKAST once a day in the evening with or without food, as your physician has prescribed.

Take AG-MONTELUKAST daily for as long as your physician prescribes it in order to maintain control of your or your child’s asthma. AG-MONTELUKAST can treat your or your child’s asthma only if you or your child continue to take it.

It is important that you or your child continue taking AG-MONTELUKAST daily as prescribed by your physician, even when you or your child has no symptoms or if you or your child has an asthma attack.

If you are taking other medications along with AG-MONTELUKAST your physician will instruct you how and when to take each medication. Your physician will increase or decrease the doses of these medications as needed.

Seasonal Allergic Rhinitis (for adults and adolescents 15 years and older):

Take AG-MONTELUKAST once a day in the evening with or without food, as your physician has prescribed.

Remember that your physician has prescribed this medicine only for you or your child. Never give it to anyone else.

Follow up with your physician to ensure your continued health and safety.

Overdose:

If you think you have taken too much AG-MONTELUKAST, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

Try to take AG-MONTELUKAST as prescribed. However, if you miss a dose, just resume the usual schedule of one tablet once daily.

IMPORTANT: PLEASE READ

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Any medicine may have unintended or undesirable effects, so-called side effects. AG-MONTELUKAST is generally well-tolerated.

The most common side effects reported were;

  • abdominal pain
  • headache
  • thirst
  • diarrhea
  • hyperactivity
  • asthma
  • scaly and itchy skin
  • rash

These were usually mild.

Additionally, the following have been reported:

  • upper respiratory tract infection (common cold)
  • feeling anxious, irritability, disturbance in attention,
  • memory impairment, restlessness, sleep walking, sleep disorders including dream abnormalities and insomnia, uncontrolled muscle movements
  • dizziness, drowsiness, pins and needles/numbness
  • nose bleed
  • joint pain, muscle aches and muscle cramps tender red lumps under the skin, most commonly on your shins
  • weakness/tiredness, fatigue
  • swelling
  • fever
  • bedwetting in children

Tell your physician or pharmacist if you develop any of the above symptoms, any unusual symptom, or if any known symptom continues or worsens.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptoms / EffectsTalk with your physician or pharmacistStop taking drug and seek immediate emergency medical attention
Only if severeIn all cases
Rare
symptoms of allergic reactions such as swelling of the face, lips, tongue, and/or throat (which may cause difficulty in breathing or swallowing), hives, rash, and itching√
Very Rare
symptoms of liver problems: nausea, vomiting, fatigue, jaundice (yellowing of the skin and eyes), dark urine, flu-like symptoms, loss of appetite, and pain in your abdomen√
increased bleeding tendency, bruising, low blood platelet count√
severe skin reactions (erythema multiforme) that may occur without warning√
behavior and mood related changes [agitation including aggressive behavior or hostility (such as temper tantrums in children)]√
depression√
disorientation (inability to know correct time, place or person)√
suicidal thoughts and actions√
tremor√
hallucinations (seeing or hearing things that are not there)√
seizure (convulsions or fits)√
palpitations (heart skips a beat)√

IMPORTANT: PLEASE READ

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptoms / EffectsTalk with your physician or pharmacistStop taking drug and seek immediate emergency medical attention
Only if severeIn all cases
Churg-Strauss syndrome: a flu-like illness, rash, pins and needles or numbness of arms or legs, joint pain and severe sinusitis√
swelling (inflammation) of the lungs: breathing problems that continue to get worse√

This is not a complete list of side effects. For any unexpected effects while taking AG-MONTELUKAST, contact your physician or pharmacist.

HOW TO STORE IT

Store the 4 mg and 5 mg chewable tablets and the 10 mg film-coated tablets at room temperature (15°C-30°C). Protect from moisture and light. For blister package keep tablets in original package

Keep out of the reach and sight of children

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

If you want more information about AG-MONTELUKAST:

  • Talk to your healthcare professional
  • Find the full product monograph that is prepared for healthcare professionals and includes this Consumer Information by visiting Health Canada website (http://hc-sc.gc.ca/index-eng.php); or by calling 450-449-9272.

Date of Revision: November 20, 2018.

IMPORTANT: PLEASE READ

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02482819

Revision date stated in the text: November 20, 2018

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for AG-Montelukast (Angita Pharma, 4 mg, 5 mg)

Rx or OTC
Prescription (Rx)?
DIN 02482819, 02482827
Schedule(s) PRESCRIPTION
Active ingredient(s) Montelukast (montelukast sodium)
Dosage form(s) Tablet (Chewable)
Route(s) of administration Oral
Drug class (WHO ATC)
  1. R Respiratory system drugs
    1. R03 Drugs for obstructive airway diseases
      1. R03D Other systemic drugs for obstructive airway diseases
        1. R03DC Leukotriene receptor antagonists for obstructive airway diseases
          1. R03DC03 Montelukast
Company ANGITA PHARMA INC.
Current status Cancelled Pre Market
Current status date December 20, 2022
Strengths and forms
DIN Strength Dosage form(s) Current status
02482819 4 MG Tablet (Chewable) Cancelled Pre Market December 20, 2022
02482827 5 MG Tablet (Chewable) Cancelled Pre Market December 20, 2022

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.